Dave M. Denton is the Chief Financial Officer and Executive Vice President for Pfizer. Dave is a member of Pfizer’s Executive Leadership Team (ELT), providing strategic global financial leadership. Dave leads the corporate finance functions including audit, treasury, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics.

Dave has more than 25 years of finance and operational expertise, including more than 20 years in the healthcare sector. As a result, he brings to Pfizer a unique perspective on the role of payers, the needs of patients, and the rapidly evolving healthcare landscape.

Prior to joining Pfizer, Dave was the CFO and Executive Vice President of Lowe’s Companies Inc. He joined Lowes in 2018 and was responsible for all of Lowe’s financial functions and processes. This includes corporate finance and treasury, strategy, real estate, accounting, tax, internal audit and risk management.

Before joining Lowe's, he served as executive vice president and CFO of CVS Health, where he was responsible for all aspects of financial planning and management. Dave played a key role in CVS’s transformational journey from a retail pharmacy to the health solutions company it is today and led the full integration of Caremark into CVS. In December 2017, he played a pivotal role in one of the largest healthcare transactions in history when CVS acquired Aetna - structuring and negotiating the terms and financing for the transaction.

Before being named the CFO of CVS Health, Dave held several leadership roles at CVS, including Senior Vice President and Controller/Chief Accounting Officer. Prior to CVS, Dave was with the management consulting firm of Deloitte Touche Tohmatsu.

Dave earned a bachelor's degree in business administration from Kansas State University and an MBA from the Babcock Graduate School of Management at Wake Forest University. Additionally, since March 1, 2023, Dave has served on the Board of Directors of Haleon PLC and he served on the board of Tapestry, Inc. for nine years from 2014 – 2023.